Fluticasone furoate, umeclidinium and vilanterol once-daily single inhaler triple therapy

Description

In this Product Explainer, Respiratory Physician Dr Adrian Barnett explains the role of fluticasone furoate, umeclidinium and vilanterol once-daily single inhaler triple therapy for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-240005 Approved September 2024.

Dr Adrian Barnett

expert

Dr Adrian Barnett

Respiratory Physician, Gold Coast University Hospital

Date published: 12 November 2024